ALT · Altimmune, Inc.

The filing documents a material corporate governance action: Altimmune’s increase in authorized common stock, which expands flexibility for future capital-raising, strategic transactions, or equity-based compensation. While not immediately dilutive, the change lowers procedural barriers to issuing new shares — a consideration for investors assessing potential dilution risk or strategic optionality. The vote results reveal nuanced shareholder sentiment: Proposal No. 4 passed decisively among votes cast (72.5% in favor), but the high volume of broker non-votes (35.9M across multiple proposals) suggests limited discretionary voting authority by brokers on non-routine matters — consistent with NYSE rules. Director elections showed uniform election but elevated withhold rates (3.7–5.6% of total shares entitled to vote), signaling possible concerns about board oversight or strategy. The say-on-pay outcome — with 30% of votes cast opposed and nearly all broker votes withheld — indicates meaningful dissatisfaction with executive pay practices, warranting review of the proxy statement disclosures. Collectively, these outcomes reflect an engaged but critical shareholder base navigating a pre-commercial biopharma company’s capital structure and governance posture.